Somewhat Favorable News Coverage Somewhat Unlikely to Affect Syndax Pharmaceuticals (SNDX) Stock Price

Media stories about Syndax Pharmaceuticals (NASDAQ:SNDX) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.1329322955315 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Syndax Pharmaceuticals (NASDAQ SNDX) opened at 10.97 on Friday. The firm’s market capitalization is $243.74 million. The firm’s 50 day moving average is $11.89 and its 200-day moving average is $11.89. Syndax Pharmaceuticals has a 12 month low of $6.31 and a 12 month high of $13.48.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.09. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.31 million. Syndax Pharmaceuticals had a negative return on equity of 58.23% and a negative net margin of 4,294.59%. On average, analysts expect that Syndax Pharmaceuticals will post ($3.11) EPS for the current fiscal year.

Several equities analysts have recently weighed in on the stock. Nomura decreased their price target on shares of Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 11th. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Morgan Stanley restated an “overweight” rating and set a $25.00 price objective (up from $24.00) on shares of Syndax Pharmaceuticals in a research report on Monday, July 10th. Oppenheimer Holdings, Inc. raised their price objective on shares of Syndax Pharmaceuticals to $29.00 and gave the stock an “outperform” rating in a research report on Friday, August 11th. Finally, Instinet restated a “buy” rating and set a $22.00 price objective (down from $27.00) on shares of Syndax Pharmaceuticals in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Syndax Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $23.13.

COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/syndax-pharmaceuticals-sndx-receiving-somewhat-positive-media-coverage-report-shows.html.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Insider Buying and Selling by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply